The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Author:
Khoury Joseph D.ORCID, Solary EricORCID, Abla Oussama, Akkari YassmineORCID, Alaggio Rita, Apperley Jane F.ORCID, Bejar RafaelORCID, Berti Emilio, Busque LambertORCID, Chan John K. C., Chen WeinaORCID, Chen Xueyan, Chng Wee-Joo, Choi John K.ORCID, Colmenero IsabelORCID, Coupland Sarah E., Cross Nicholas C. P.ORCID, De Jong Daphne, Elghetany M. Tarek, Takahashi EmikoORCID, Emile Jean-FrancoisORCID, Ferry Judith, Fogelstrand Linda, Fontenay Michaela, Germing Ulrich, Gujral Sumeet, Haferlach TorstenORCID, Harrison Claire, Hodge Jennelle C., Hu ShiminORCID, Jansen Joop H., Kanagal-Shamanna RashmiORCID, Kantarjian Hagop M.ORCID, Kratz Christian P.ORCID, Li Xiao-Qiu, Lim Megan S., Loeb Keith, Loghavi SanamORCID, Marcogliese Andrea, Meshinchi Soheil, Michaels Phillip, Naresh Kikkeri N.ORCID, Natkunam YasodhaORCID, Nejati Reza, Ott German, Padron EricORCID, Patel Keyur P., Patkar NikhilORCID, Picarsic Jennifer, Platzbecker UweORCID, Roberts Irene, Schuh AnnaORCID, Sewell William, Siebert Reiner, Tembhare PrashantORCID, Tyner JeffreyORCID, Verstovsek SrdanORCID, Wang WeiORCID, Wood Brent, Xiao WenbinORCID, Yeung CeciliaORCID, Hochhaus AndreasORCID
Abstract
AbstractThe upcoming 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers arising in various organ systems within a single relational database. This paper summarizes the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms and provides an overview of the principles and rationale underpinning changes from the prior edition. The definition and diagnosis of disease types continues to be based on multiple clinicopathologic parameters, but with refinement of diagnostic criteria and emphasis on therapeutically and/or prognostically actionable biomarkers. While a genetic basis for defining diseases is sought where possible, the classification strives to keep practical worldwide applicability in perspective. The result is an enhanced, contemporary, evidence-based classification of myeloid and histiocytic/dendritic neoplasms, rooted in molecular biology and an organizational structure that permits future scalability as new discoveries continue to inexorably inform future editions.
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference113 articles.
1. Uttley L, Indave BI, Hyde C, White V, Lokuhetty D, Cree I. Invited commentary-WHO Classification of Tumours: How should tumors be classified? Expert consensus, systematic reviews or both? Int J Cancer. 2020;146:3516–21. 2. Salto-Tellez M, Cree IA. Cancer taxonomy: pathology beyond pathology. Eur J Cancer. 2019;115:57–60. 3. Cree I. The WHO Classification of Haematolymphoid Tumours. Leukemia. 2022;36:in press (same issue). 4. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Barreto de Oliveira Araujo I, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36:in press (same issue). 5. Bruford EA, Antonescu CR, Carroll AJ, Chinnaiyan A, Cree IA, Cross NCP, et al. HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions. Leukemia. 2021;35:3040–3.
Cited by
1134 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|